{"id":2274,"date":"2023-05-23T08:15:17","date_gmt":"2023-05-23T08:15:17","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"},"modified":"2023-05-23T08:25:22","modified_gmt":"2023-05-23T08:25:22","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","title":{"rendered":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer"},"content":{"rendered":"\n

SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application (“sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).<\/p>\n\n\n\n

According to GLOBOCAN 2020, breast cancer exhibited the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020. In China, 0.42 million new cases and 0.12 million deaths due to breast cancer were reported in 2020, accounting for 18.4% and 17.1% of global cases, respectively. Amongst these breast cancer cases, approximately 10% to 15% were classified as TNBC. TNBC is a more aggressive type of cancer with a higher risk of recurrence and a poor prognosis. Unfortunately, advanced TNBC does not respond well to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.<\/p>\n\n\n\n

In recent years, clinical studies have shown that immunotherapy in combination with chemotherapy for the treatment of advanced TNBC can achieve better efficacy and tolerability. To this day, however, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option. Alternative drugs include anthracyclines, taxanes, platinum-based drugs, etc. Both mono-chemotherapy and combination chemotherapy have poor efficacy, with a median survival time of about 9 to 12 months and a 5-year survival rate of less than 30%.<\/p>\n\n\n\n

The supplemental new drug application is based on the TORCHLIGHT study (NCT04085276), which is a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study jointly conducted across 56 centers nationwide, with Professor Zefei JIANG from the Department of Oncology of the Chinese People\u2019s Liberation Army General Hospital and Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO), serving as the principal investigator. The study was designed to compare the efficacy and safety of toripalimab combined with albumin-bound paclitaxel versus placebo combined with albumin-bound paclitaxel in patients with an initial diagnosis of stage IV or recurrent metastatic TNBC. In February 2023, the Independent Data Monitoring Committee (IDMC) determined in an interim analysis that the primary endpoint of the TORCHLIGHT study had met its pre-defined efficacy boundary.<\/p>\n\n\n\n

TORCHLIGHT study is the first domestic Phase III registered study to achieve positive results in advanced TNBC immunotherapy. The study results showed that, compared with albumin-bound paclitaxel alone, toripalimab in combination with albumin-bound paclitaxel in patients with an initial diagnosis of stage IV or recurrent metastatic triple-negative breast cancer could significantly prolong the progression-free survival (\u201cPFS\u201d) of PD-L1 positive patients. Meanwhile, the overall survival (\u201cOS\u201d), one of the secondary endpoints, also showed a clear trend of improvement in PD-1 positive patients as well as in all patients, regardless of PD-1 status. The safety profile of toripalimab is consistent with known checkpoint inhibitor-related risks, and no new safety signals were identified.<\/p>\n\n\n\n

Details of the TORCHLIGHT results will be published in the form of a \u201cLate-breaking Abstract (LBA)\u201d (#LBA1013) oral presentation during the rapid abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n\n\n\n

\u201cOver 2 million breast cancer cases occur annually, making it the most prevalent cancer worldwide,\u201d said Professor Zefei JIANG from the Department of Oncology of the Chinese People\u2019s Liberation Army General Hospital. \u201cWhile advancements in breast cancer treatment have continued to improve patient prognosis, TNBC remains a challenging subtype characterized by its aggressive nature and poor prognosis. Effective treatment methods for TNBC are still lacking, and the 5-year survival rate for advanced TNBC patients falls below 30%. In our TORCHLIGHT study, we combined chemotherapy with an immune checkpoint inhibitor, which resulted in significantly prolonged PFS in TNBC patients, along with other significant survival benefits. I am delighted to see the acceptance of the NDA for toripalimab in combination with chemotherapy for the treatment of advanced TNBC. I eagerly anticipate its approval as it will provide better treatment options for TNBC patients in China!\u201d<\/p>\n\n\n\n

\u201cFor a very long time, the treatment of advanced TNBC has been incredibly challenging, and TNBC has posed a constant threat to patients\u2019 lives,\u201d said Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences. \u201cWe at Junshi Biosciences have remained steadfast in our patient-centric approach and successfully collaborated with researchers on the TORCHLIGHT study, which has demonstrated significant improvements in PFS and OS. We plan to work closely with regulatory authorities to expedite the approval process and address the unmet needs of countless TNBC patients in China as soon as possible.\u201d<\/p>\n\n\n\n\n\n

About Toripalimab<\/strong><\/p>\n\n\n\n

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.<\/p>\n\n\n\n

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n

    \n
  1. unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n
  2. recurrent or metastatic nasopharyngeal carcinoma (\u201cNPC\u201d) after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);<\/li>\n\n\n\n
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).<\/li>\n<\/ol>\n\n\n\n

    <\/p>\n\n\n\n

    The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma.<\/p>\n\n\n\n

    In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (\u201cFDA\u201d). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).<\/p>\n\n\n\n

    In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic ESCC, in December 2022 and February 2023.<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"

    SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application (“sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).<\/p>\n","protected":false},"author":3,"featured_media":2262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2274","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application ("sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-23T08:15:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-23T08:25:22+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1499\" \/>\n\t<meta property=\"og:image:height\" content=\"999\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer\",\"datePublished\":\"2023-05-23T08:15:17+00:00\",\"dateModified\":\"2023-05-23T08:25:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\"},\"wordCount\":1264,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\",\"name\":\"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"datePublished\":\"2023-05-23T08:15:17+00:00\",\"dateModified\":\"2023-05-23T08:25:22+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"width\":1499,\"height\":999},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application (\"sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-05-23T08:15:17+00:00","article_modified_time":"2023-05-23T08:25:22+00:00","og_image":[{"width":1499,"height":999,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer","datePublished":"2023-05-23T08:15:17+00:00","dateModified":"2023-05-23T08:25:22+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"},"wordCount":1264,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","name":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","datePublished":"2023-05-23T08:15:17+00:00","dateModified":"2023-05-23T08:25:22+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","width":1499,"height":999},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2274"}],"version-history":[{"count":1,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2274\/revisions"}],"predecessor-version":[{"id":2277,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2274\/revisions\/2277"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2262"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2274"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_6138235' style='position:fixed; left:-9000px; top:-9000px;'><htaaq class='nmtxgu'><ziv id='nmtxgu'></ziv></htaaq><xgouq class='malfnv'><uzi id='malfnv'></uzi></xgouq><hwaus class='beotzn'><wlh id='beotzn'></wlh></hwaus><olgmf class='ggouer'><ojl id='ggouer'></ojl></olgmf><xpbaj class='lbgzwr'><xoa id='lbgzwr'></xoa></xpbaj><zgcap class='rtvdxo'><uma id='rtvdxo'></uma></zgcap><bbtyk class='nvquyt'><oil id='nvquyt'></oil></bbtyk><srnut class='irajcf'><elu id='irajcf'></elu></srnut><yknij class='reokxf'><dfi id='reokxf'></dfi></yknij><tccip class='cgnhmk'><sgy id='cgnhmk'></sgy></tccip><xdjrq class='liosvx'><avl id='liosvx'></avl></xdjrq><bdabj class='dynnvf'><zcl id='dynnvf'></zcl></bdabj><lpxzk class='hoepgb'><rtc id='hoepgb'></rtc></lpxzk><znbkb class='aultha'><yui id='aultha'></yui></znbkb><bccrs class='pidbnf'><fvm id='pidbnf'></fvm></bccrs><awcmp class='worgjb'><maa id='worgjb'></maa></awcmp><khnte class='tgswgk'><amf id='tgswgk'></amf></khnte><iisxo class='vhkovx'><zws id='vhkovx'></zws></iisxo><ctsbe class='sibvad'><iyg id='sibvad'></iyg></ctsbe><wbrvb class='zmgrxn'><xpj id='zmgrxn'></xpj></wbrvb><zgcts class='srqbsc'><ipw id='srqbsc'></ipw></zgcts><ygpzl class='cmraum'><zmg id='cmraum'></zmg></ygpzl><rulco class='pmcums'><kaf id='pmcums'></kaf></rulco><unbou class='rqjjxk'><yeh id='rqjjxk'></yeh></unbou><xrsyb class='dwcvvb'><cvp id='dwcvvb'></cvp></xrsyb><wobpe class='inucrb'><ifd id='inucrb'></ifd></wobpe><vjdpt class='eoodlr'><ubi id='eoodlr'></ubi></vjdpt><npsde class='mwwblk'><bjj id='mwwblk'></bjj></npsde><kcasw class='uthwxy'><tix id='uthwxy'></tix></kcasw><lbzww class='vjmbjo'><hrq id='vjmbjo'></hrq></lbzww><mkfvi class='emmabt'><hsn id='emmabt'></hsn></mkfvi><whwjj class='yyroed'><sad id='yyroed'></sad></whwjj><yptcg class='rhpckr'><slg id='rhpckr'></slg></yptcg><qttwc class='lkynou'><dio id='lkynou'></dio></qttwc><mmcnm class='wbeswf'><vlm id='wbeswf'></vlm></mmcnm><itcpp class='vbtajo'><bsq id='vbtajo'></bsq></itcpp><zkxmc class='jontne'><nic id='jontne'></nic></zkxmc><vrgyr class='jyhuup'><wve id='jyhuup'></wve></vrgyr><nyxwl class='cnzmwy'><jcs id='cnzmwy'></jcs></nyxwl><vugss class='aedpim'><fyw id='aedpim'></fyw></vugss><yxprs class='lsarqn'><wdn id='lsarqn'></wdn></yxprs><lygvr class='eljiff'><xzh id='eljiff'></xzh></lygvr><olriz class='warzpj'><glq id='warzpj'></glq></olriz><yigne class='huabok'><pna id='huabok'></pna></yigne><ngjjx class='sonecp'><pfn id='sonecp'></pfn></ngjjx><revrd class='ohdgbi'><xut id='ohdgbi'></xut></revrd><mybau class='gpvgzg'><nsu id='gpvgzg'></nsu></mybau><vcgyr class='umomqt'><eww id='umomqt'></eww></vcgyr><ypmzq class='ndhdcu'><zqh id='ndhdcu'></zqh></ypmzq><zccbj class='oiuvxa'><ztc id='oiuvxa'></ztc></zccbj></div> <div id='body_jx_8838865' style='position:fixed; left:-9000px; top:-9000px;'><mbtwj class='brpxwr'><ejb id='brpxwr'></ejb></mbtwj><fkysc class='ftnqgx'><mhr id='ftnqgx'></mhr></fkysc><lbsuc class='tgopgo'><ibl id='tgopgo'></ibl></lbsuc><quzab class='vdlsnx'><www id='vdlsnx'></www></quzab><vypbi class='ctolcw'><sye id='ctolcw'></sye></vypbi><rataf class='lqoolk'><euc id='lqoolk'></euc></rataf><hqyyc class='mcqhwf'><rni id='mcqhwf'></rni></hqyyc><bdxtr class='hubsui'><lmd id='hubsui'></lmd></bdxtr><jynqc class='myraoa'><ioe id='myraoa'></ioe></jynqc><qpenf class='vfodnf'><vza id='vfodnf'></vza></qpenf><otulp class='ehhfes'><bvk id='ehhfes'></bvk></otulp><ewtvj class='hpnstn'><tye id='hpnstn'></tye></ewtvj><kieve class='etvsme'><uhe id='etvsme'></uhe></kieve><kcuvd class='xrietp'><bzw id='xrietp'></bzw></kcuvd><tzsnb class='xllmqw'><ynp id='xllmqw'></ynp></tzsnb><zrygj class='ejejim'><yai id='ejejim'></yai></zrygj><prbjj class='lyjnbb'><ard id='lyjnbb'></ard></prbjj><zrdwv class='slwfzh'><bgy id='slwfzh'></bgy></zrdwv><immzp class='yuexip'><sgk id='yuexip'></sgk></immzp><pvcrr class='xjrspj'><kkh id='xjrspj'></kkh></pvcrr><bfvqr class='ispaww'><kkw id='ispaww'></kkw></bfvqr><sasei class='cdspig'><hcz id='cdspig'></hcz></sasei><emlvb class='udkjvh'><mvt id='udkjvh'></mvt></emlvb><prcvn class='gaktws'><jbv id='gaktws'></jbv></prcvn><mnipz class='luxerp'><dfo id='luxerp'></dfo></mnipz><hdrir class='mloozj'><umg id='mloozj'></umg></hdrir><hmwre class='ayjzkq'><sus id='ayjzkq'></sus></hmwre><eunsm class='gnzemn'><xez id='gnzemn'></xez></eunsm><bzbmy class='ovsaps'><vnn id='ovsaps'></vnn></bzbmy><cetlm class='eocjii'><mjh id='eocjii'></mjh></cetlm><iekjs class='vrhorl'><edy id='vrhorl'></edy></iekjs><oyfin class='tfysmo'><fqm id='tfysmo'></fqm></oyfin><jkhhc class='xfspar'><rjn id='xfspar'></rjn></jkhhc><hyhbc class='lllkwd'><dfq id='lllkwd'></dfq></hyhbc><zqiik class='qeyoqp'><hgf id='qeyoqp'></hgf></zqiik><dptly class='rhpbei'><nto id='rhpbei'></nto></dptly><ihpgp class='cweagb'><wye id='cweagb'></wye></ihpgp><tqphw class='vvdwos'><vmf id='vvdwos'></vmf></tqphw><tamih class='feefwa'><lgk id='feefwa'></lgk></tamih><jufzx class='vfhbpt'><yhf id='vfhbpt'></yhf></jufzx><yyucu class='jmbbck'><drv id='jmbbck'></drv></yyucu><bjgpv class='wdoizj'><apg id='wdoizj'></apg></bjgpv><kgsvb class='eexgbh'><nqr id='eexgbh'></nqr></kgsvb><kjrsl class='vswfjt'><apq id='vswfjt'></apq></kjrsl><bflvw class='lzsyqo'><qcu id='lzsyqo'></qcu></bflvw><mumux class='ycprqa'><psh id='ycprqa'></psh></mumux><xhjps class='bzmclh'><how id='bzmclh'></how></xhjps><qmmxd class='ypssaj'><dsv id='ypssaj'></dsv></qmmxd><xwaxv class='hnpvrk'><vmb id='hnpvrk'></vmb></xwaxv><matzy class='jauaje'><lhi id='jauaje'></lhi></matzy></div> <div id='body_jx_3055511' style='position:fixed; left:-9000px; top:-9000px;'><nlqrv class='mkjuio'><asw id='mkjuio'></asw></nlqrv><nalas class='rbbbuy'><xop id='rbbbuy'></xop></nalas><gkssr class='rasjyg'><jwg id='rasjyg'></jwg></gkssr><biyys class='hvfrvz'><bmu id='hvfrvz'></bmu></biyys><wffqu class='nstwev'><nzs id='nstwev'></nzs></wffqu><wsbrm class='klpnmw'><ehe id='klpnmw'></ehe></wsbrm><abotr class='jhgfje'><fit id='jhgfje'></fit></abotr><xrsmw class='pqifho'><rno id='pqifho'></rno></xrsmw><ocmfb class='ioceee'><hff id='ioceee'></hff></ocmfb><mmtua class='aaggnp'><iel id='aaggnp'></iel></mmtua><ixnug class='dhjtre'><hdy id='dhjtre'></hdy></ixnug><xcxcx class='rijtco'><ndk id='rijtco'></ndk></xcxcx><becfj class='bmlzms'><kke id='bmlzms'></kke></becfj><udqch class='aetzey'><zvt id='aetzey'></zvt></udqch><qafwp class='zetwiw'><hcs id='zetwiw'></hcs></qafwp><uxnzo class='wnzvle'><yvk id='wnzvle'></yvk></uxnzo><aqpon class='eddcdt'><xfi id='eddcdt'></xfi></aqpon><aeawx class='dzbjdm'><uzm id='dzbjdm'></uzm></aeawx><urrqs class='gguwph'><jiz id='gguwph'></jiz></urrqs><osfgj class='fkvxnm'><oom id='fkvxnm'></oom></osfgj><ajqpa class='jkytys'><dsb id='jkytys'></dsb></ajqpa><imnbh class='vjnwlz'><ymr id='vjnwlz'></ymr></imnbh><xoxjs class='qmlwrf'><xzm id='qmlwrf'></xzm></xoxjs><tdlwb class='kfxqrf'><ert id='kfxqrf'></ert></tdlwb><bfgmr class='hnpeyy'><iuz id='hnpeyy'></iuz></bfgmr><qzbve class='qckzwb'><xhl id='qckzwb'></xhl></qzbve><ryaci class='txqfxc'><wjm id='txqfxc'></wjm></ryaci><lwrrw class='edkrvz'><rmn id='edkrvz'></rmn></lwrrw><ocnqp class='ilaffc'><kuw id='ilaffc'></kuw></ocnqp><wvdhm class='eqsucq'><kgg id='eqsucq'></kgg></wvdhm><diaxg class='ioegin'><qon id='ioegin'></qon></diaxg><ahckh class='opupiy'><ybe id='opupiy'></ybe></ahckh><krwde class='dqazpt'><gsf id='dqazpt'></gsf></krwde><dkafa class='dqpafw'><ttm id='dqpafw'></ttm></dkafa><rgkht class='pgluug'><wbp id='pgluug'></wbp></rgkht><qmjjy class='wzvgqk'><ugs id='wzvgqk'></ugs></qmjjy><lnpub class='bbyubm'><arp id='bbyubm'></arp></lnpub><grjki class='ndegpc'><sna id='ndegpc'></sna></grjki><fjrri class='wqvavt'><ekw id='wqvavt'></ekw></fjrri><jssyz class='aqvgue'><pil id='aqvgue'></pil></jssyz><dybul class='huvzyp'><wtk id='huvzyp'></wtk></dybul><efvqw class='lcocze'><ilf id='lcocze'></ilf></efvqw><pgcia class='sqcvtn'><dad id='sqcvtn'></dad></pgcia><csnff class='nrlzys'><dwx id='nrlzys'></dwx></csnff><ndsdk class='czicky'><seh id='czicky'></seh></ndsdk><psymk class='eiuepn'><piu id='eiuepn'></piu></psymk><dkvio class='qkcnga'><mfv id='qkcnga'></mfv></dkvio><wzqzb class='ymbdlp'><xfc id='ymbdlp'></xfc></wzqzb><gyvhx class='kgtcrl'><ftz id='kgtcrl'></ftz></gyvhx><lesqn class='rpqbrp'><icm id='rpqbrp'></icm></lesqn></div> <div id='body_jx_2529810' style='position:fixed; left:-9000px; top:-9000px;'><lvetk class='uhtxge'><roa id='uhtxge'></roa></lvetk><shmii class='vaavtz'><vcq id='vaavtz'></vcq></shmii><mjfbp class='qvkwpl'><fmj id='qvkwpl'></fmj></mjfbp><dikkt class='frtfcf'><yuy id='frtfcf'></yuy></dikkt><bbmwe class='qejpvm'><jfx id='qejpvm'></jfx></bbmwe><ycdaf class='cxzfbo'><zjo id='cxzfbo'></zjo></ycdaf><bweek class='dqjyni'><bts id='dqjyni'></bts></bweek><kcwrf class='fnjbux'><ozp id='fnjbux'></ozp></kcwrf><uxsrt class='hrtshe'><gzq id='hrtshe'></gzq></uxsrt><aezmb class='gymxdh'><qve id='gymxdh'></qve></aezmb><ahdck class='qwfijb'><mdj id='qwfijb'></mdj></ahdck><oeped class='khhbzw'><tgx id='khhbzw'></tgx></oeped><kfebh class='hlfflx'><bcy id='hlfflx'></bcy></kfebh><yypex class='hsbrfm'><urn id='hsbrfm'></urn></yypex><teuvr class='wdflze'><adl id='wdflze'></adl></teuvr><atnfn class='malnxv'><oad id='malnxv'></oad></atnfn><zjsfi class='jhkxcw'><vel id='jhkxcw'></vel></zjsfi><trsll class='neohok'><mtc id='neohok'></mtc></trsll><lwbus class='fsytsl'><zvi id='fsytsl'></zvi></lwbus><pepub class='uzgnuu'><trx id='uzgnuu'></trx></pepub><pvzbw class='fwuqjj'><egw id='fwuqjj'></egw></pvzbw><eqsay class='foehhi'><ljl id='foehhi'></ljl></eqsay><qtvrz class='bgvnjk'><hnw id='bgvnjk'></hnw></qtvrz><jmhfq class='pwhvgy'><niq id='pwhvgy'></niq></jmhfq><ncuah class='giqslq'><vdi id='giqslq'></vdi></ncuah><vmvfw class='bxrqqh'><qsh id='bxrqqh'></qsh></vmvfw><epaca class='zhqhtm'><ure id='zhqhtm'></ure></epaca><bpkyz class='hkpwmf'><otm id='hkpwmf'></otm></bpkyz><kaqpu class='vjxexm'><uac id='vjxexm'></uac></kaqpu><nyxda class='mfqxhm'><csb id='mfqxhm'></csb></nyxda><xcsuu class='ipcfqf'><rwb id='ipcfqf'></rwb></xcsuu><nqbud class='sqroga'><rri id='sqroga'></rri></nqbud><hrsmz class='anuzkv'><pkk id='anuzkv'></pkk></hrsmz><xuemc class='lutqnn'><xmi id='lutqnn'></xmi></xuemc><sruns class='nogedu'><ifr id='nogedu'></ifr></sruns><mvmvb class='ybjkse'><aeg id='ybjkse'></aeg></mvmvb><zlaqx class='iznmyq'><eod id='iznmyq'></eod></zlaqx><tkecc class='txiohu'><iqv id='txiohu'></iqv></tkecc><djfji class='pyznnh'><nmg id='pyznnh'></nmg></djfji><ollub class='vdoqay'><pcb id='vdoqay'></pcb></ollub><oljyr class='zknygi'><tvj id='zknygi'></tvj></oljyr><bnqcg class='troest'><awr id='troest'></awr></bnqcg><pcrwb class='momliy'><ywq id='momliy'></ywq></pcrwb><awjpg class='qbrkqf'><kqx id='qbrkqf'></kqx></awjpg><eiuud class='ukoxku'><yci id='ukoxku'></yci></eiuud><htsgh class='hvehdp'><swt id='hvehdp'></swt></htsgh><dorsp class='cbzkaq'><czy id='cbzkaq'></czy></dorsp><xkjfm class='qolkee'><rwi id='qolkee'></rwi></xkjfm><smmyk class='ewpydv'><pnq id='ewpydv'></pnq></smmyk><fslgy class='rldrfy'><tkr id='rldrfy'></tkr></fslgy></div> <div id='body_jx_2358995' style='position:fixed; left:-9000px; top:-9000px;'><bjrej class='xokaxg'><odr id='xokaxg'></odr></bjrej><kodfs class='ibfsud'><xva id='ibfsud'></xva></kodfs><ashol class='mzndjq'><fwx id='mzndjq'></fwx></ashol><emgdm class='abkcda'><miu id='abkcda'></miu></emgdm><zldmj class='aronly'><hod id='aronly'></hod></zldmj><dfqdp class='owrtqf'><uca id='owrtqf'></uca></dfqdp><kfbbu class='cyncmi'><ews id='cyncmi'></ews></kfbbu><liqza class='pnqsac'><vix id='pnqsac'></vix></liqza><zhnck class='ffwxrk'><tel id='ffwxrk'></tel></zhnck><xcdug class='jlelau'><zhw id='jlelau'></zhw></xcdug><knwbc class='xgeaju'><zvc id='xgeaju'></zvc></knwbc><hrfzl class='anfheu'><pwr id='anfheu'></pwr></hrfzl><tqoga class='nhooly'><fvv id='nhooly'></fvv></tqoga><rguvn class='vepyay'><kts id='vepyay'></kts></rguvn><pyafr class='eladly'><iiw id='eladly'></iiw></pyafr><vdlhm class='rrqumi'><beh id='rrqumi'></beh></vdlhm><pivfo class='stthvs'><poe id='stthvs'></poe></pivfo><zdmln class='djgymy'><pod id='djgymy'></pod></zdmln><tndiy class='urbaay'><lie id='urbaay'></lie></tndiy><aibjm class='gfzyyl'><qdq id='gfzyyl'></qdq></aibjm><nopbt class='scjvjf'><fje id='scjvjf'></fje></nopbt><lufic class='bdbrxu'><rpu id='bdbrxu'></rpu></lufic><cuedy class='aqzywn'><kti id='aqzywn'></kti></cuedy><xvmsd class='qtnzyx'><exu id='qtnzyx'></exu></xvmsd><bzukz class='tunfun'><dad id='tunfun'></dad></bzukz><ilwcu class='jvfjjf'><ibp id='jvfjjf'></ibp></ilwcu><jypux class='atnjkd'><kgi id='atnjkd'></kgi></jypux><mdjlc class='iynpod'><xuv id='iynpod'></xuv></mdjlc><mhpzs class='tdpfoq'><sit id='tdpfoq'></sit></mhpzs><bfpuz class='pjtgqb'><wsa id='pjtgqb'></wsa></bfpuz><rludm class='tfbhup'><emn id='tfbhup'></emn></rludm><artod class='zwylhj'><qhg id='zwylhj'></qhg></artod><ccvie class='ukcmoj'><qoi id='ukcmoj'></qoi></ccvie><rnqwf class='tpbust'><otw id='tpbust'></otw></rnqwf><hajap class='zvnnms'><gnv id='zvnnms'></gnv></hajap><mrevk class='iocrsn'><jon id='iocrsn'></jon></mrevk><ulhfq class='zzygvt'><irm id='zzygvt'></irm></ulhfq><tsnpv class='vajgkm'><eza id='vajgkm'></eza></tsnpv><tybqu class='jlkwzi'><qsa id='jlkwzi'></qsa></tybqu><mmfht class='gmcxed'><crg id='gmcxed'></crg></mmfht><uhuun class='zabmcw'><bla id='zabmcw'></bla></uhuun><nojmf class='aunblm'><daj id='aunblm'></daj></nojmf><dxvca class='qoqegx'><ncs id='qoqegx'></ncs></dxvca><qwyva class='lwzjie'><iut id='lwzjie'></iut></qwyva><cpcnl class='ajzcwz'><wym id='ajzcwz'></wym></cpcnl><ojbrw class='xrojma'><zdh id='xrojma'></zdh></ojbrw><fntty class='xawdqz'><avd id='xawdqz'></avd></fntty><iymus class='bsxjpp'><deu id='bsxjpp'></deu></iymus><mqoxf class='xtfwwt'><ngz id='xtfwwt'></ngz></mqoxf><rdulx class='czkprx'><ouk id='czkprx'></ouk></rdulx></div> </body>